Literature DB >> 30938834

The value of the free androgen index depends on the phenotype of polycystic ovary syndrome - a single-centre experience.

Katarzyna Ożga1, Magdalena Krzyczkowska-Sendrakowska2, Alicja Hubalewska-Dydejczyk3, Aleksandra Gilis-Januszewska3, Maciej Ratajczak4, Magdalena Ratajczak5, Zlata Chaykivska6, Robert Jach2.   

Abstract

INTRODUCTION: The free androgen index (FAI) values differ among patients with polycystic ovarian syndrome; however, the differences are not fully understood or known. The aim of the study was to evaluate FAI in women with polycystic ovary syndrome (PCOS) in regard to the phenotype of the PCOS and insulin resistance status.
MATERIAL AND METHODS: Anthropometric, hormonal, and biochemical parameters were assessed in 312 recruited women with PCOS. The FAI values were calculated in the reproductive and metabolic phenotypes of PCOS in groups of insulin resistance status based on the homeostasis model assessment-insulin resistance (HOMA-IR) > 2.0 or fasting insulin (FI) > 10 mmol/L. To test the relationship between individual variables, Spearman's correlation analysis, the Kolmogorov-Smirnov test, and Student's t-test were used.
RESULTS: The correlation between FAI values and HOMA-IR and FI was 0.42 and 0.47, respectively, in PCOS patients. A two fold higher FAI value was observed in metabolic PCOS phenotype when compared to the reproductive one (8.51 ± 5.56 vs. 4.40 ± 2.45 for HOMA-IR and 8.73 ± 6.09 vs. 4.31 ± 3.39 for FI, respectively; p < 0.05).
CONCLUSIONS: PCOS patients are not a homogenous group in terms of FAI value. Patients with metabolic PCOS phenotype are characterised by two-fold higher FAI values compared with reproductive PCOS phenotype. Further studies on the metabolic and androgenic status of different types of PCOS phenotypes should be carried out.

Entities:  

Keywords:  free androgen index; hyperandrogenism; insulin resistance; polycystic ovary syndrome

Year:  2019        PMID: 30938834     DOI: 10.5603/EP.a2019.0017

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  2 in total

1.  Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism.

Authors:  Małgorzata Kałużna; Tomasz Krauze; Katarzyna Ziemnicka; Katarzyna Wachowiak-Ochmańska; Jolanta Kaczmarek; Adam Janicki; Andrzej Wykrętowicz; Marek Ruchała; Przemysław Guzik
Journal:  Endocrine       Date:  2021-02-22       Impact factor: 3.633

2.  Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial.

Authors:  Cheng-Ming Ni; Wen-Long Huang; Yan-Min Jiang; Juan Xu; Ru Duan; Yun-Long Zhu; Xu-Ping Zhu; Xue-Mei Fan; Guo-An Luo; Yi-Ming Wang; Yan-Yu Li; Qing He; Lan Xu
Journal:  Trials       Date:  2020-02-11       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.